Blockchain Registration Transaction Record

Clene Advances ALS Treatment with FDA-Backed Biomarker Analysis

Clene Inc. prepares for neurofilament biomarker analyses in ALS treatment, following FDA feedback, aiming to advance therapy for neurodegenerative diseases.

This news is significant as it highlights a critical step forward in the treatment of ALS and other neurodegenerative diseases. The FDA's support for Clene's biomarker analysis underscores the potential of CNM-Au8(R) to offer a new therapeutic avenue for patients with limited treatment options. The focus on neurofilament light chain as a biomarker could also pave the way for more personalized and effective treatments, marking a pivotal moment in neurodegenerative disease research.